Clinical context: Current concepts of coronary heart disease management

American Journal of Medicine

Volumn 110, Issue 6 SUPPL. 1, 2001, Pages 3-11

  Jacobson, T A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; TOXICITY;

EID: 0035897105     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(01)00672-6     Document Type: Review

References (36)

1. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham study
2. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
3. Prevalence of high blood cholesterol among US adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Cholesterol reduction and its impact on coronary artery disease and total mortality
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
8. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
9. Impact of evidence-based "clinical judgement" on the number of American adults requiring lipid-lowering therapy based on updated NHANES data
10. The cholesterol population model: US population requirements for treatment of hyperlipidemia
11. Maximizing the cost-effectiveness of lipid-lowering therapy
12. Lipid management: Current diet and drug treatment options
13. Current perspectives on statins
14. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
15. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS)
16. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Atherosclerosis Intervention Trial
17. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
18. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
19. Effect of simvastatin on coronary atheroma: The Multicentre Anti-atheroma Study
20. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
21. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
22. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study
23. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
24. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
25. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
26. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
27. Compliance with and efficacy of treatment with pravastatin and cholestyramine: A randomized study on lipid-lowering in primary care
28. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin
29. Economic benefits of aggressive lipid lowering: A managed care perspective
30. Preventing coronary heart disease in the managed care era: Improving the cost effectiveness of lipid-lowering therapy with HMG-CoA reductase inhibitors
31. Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy: An illustrative example focusing on the primary prevention of coronary heart disease in Canada
32. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed care organization